文献速递糖尿病

自动胰岛素输注在老年及高危1型糖尿病患者中的血糖与心理社会结局:系统评价与Meta分析

Glycemic and psychosocial outcomes of automated insulin delivery in older and high-risk populations with type 1 diabetes: a systematic review and meta-analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2026-09-30

心理社会福祉无显著差异,糖尿病酮症酸中毒和严重低血糖事件无显著变化。

要点

  • AID使老年及高危1型糖尿病患者TIR提高11.38%,相当于每日增加2.7小时。
  • TIR改善见于日间(8.70%)和夜间(13.35%),商用与非商用系统效果相当。
  • 心理社会福祉无显著改善,糖尿病酮症酸中毒和严重低血糖事件无显著差异。

核心结论

  • AID在老年及高危1型糖尿病患者中显示出有利的血糖结局和安全性,心理社会结局无显著改善。

研究设计与样本

  • 系统评价与Meta分析,检索CENTRAL、PubMed、Web of Science、Scopus和ClinicalTrials.gov从建库至2026年3月10日。
  • 主要结局为目标范围内时间(3.9-10.0 mmol/L [70-180 mg/dL]),采用随机效应模型合并效应量(PROSPERO,CRD420251273526)。

主要发现

  • AID使TIR提高11.38%(95%CI 8.07-14.70;I2=70%;P<.0001;极低确定性;相当于每日2.7小时)。
  • TIR改善见于日间(8.70%;95%CI 5.18-12.22%)和夜间(13.35%;95%CI 11.07-15.62%)。
  • 商用与非商用系统的TIR改善程度相当。
  • AID减少高血糖时间(-7.89%)和低血糖时间(-1.16%)。
  • 心理社会福祉(Gold、Clarke和低血糖恐惧调查评分)无显著差异,糖尿病酮症酸中毒和严重低血糖事件无显著差异。

临床怎么用

  • 对于老年(≥60岁)及高危1型糖尿病患者,AID可考虑用于改善TIR并减少高血糖和低血糖时间。
  • 商用与非商用AID系统在血糖改善方面效果相当,可根据可及性选择。
  • AID未显著改善心理社会福祉,临床仍需关注低血糖恐惧等心理社会问题。

局限性

  • 证据确定性为极低。
  • 纳入研究异质性较高(I2=70%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Automated insulin delivery (AID) has revolutionized care for people with type 1 diabetes. However, its efficacy and safety in older adults (≥60 years) and high-risk populations, including those with impaired awareness of hypoglycemia, or cognitive or functional impairment, have not been systematically evaluated. MATERIALS AND METHODS: CENTRAL, PubMed, Web of Science, Scopus, and ClinicalTrials.gov from inception to March 10, 2026. Studies on automated insulin delivery in older and high-risk individuals with type 1 diabetes were included. The primary outcome was time in range (3.9-10.0 mmol/L [70-180 mg/dL]). Secondary outcomes included time above range, time below range, psychosocial well-being (Gold, Clarke, and Hypoglycemia Fear Survey score), and serious adverse events. Pooled effect sizes were estimated with random-effects models (PROSPERO, CRD420251273526). RESULTS: Twenty-three studies involving 967 participants (11 randomized controlled trials, 3 single-arm, and 9 cohort studies) were included. Automated insulin delivery increased time in range by 11.38% (95% CI: 8.07-14.70; I2 = 70%; P < .0001; very low certainty; equivalent to 2.7 hours/day). Time in range improvement was observed during the day (8.70%; 95% CI 5.18-12.22%) and overnight (13.35%; 95% CI 11.07-15.62%). Favorable improvement was also comparable among commercial and noncommercial systems. Automated insulin delivery reduced the time spent in hyperglycemia (-7.89%) and hypoglycemia (-1.16%). No significant differences in psychosocial well-being were observed. Diabetic ketoacidosis and severe hypoglycemia events were not significant. CONCLUSION: Automated insulin delivery exhibits favorable glycemic outcomes and safety profiles in older and high-risk individuals with type 1 diabetes, suggesting potential benefits for populations traditionally considered vulnerable, although no significant improvements were observed in psychosocial outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Oktavian P, Kencono Wungu CD, Amin IM, et al. Glycemic and psychosocial outcomes of automated insulin delivery in older and high-risk populations with type 1 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2026. PMID: 42810730. doi:10.1210/clinem/dgag344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。